Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults
Invasive meningococcal disease (IMD) is rare but associated with high morbidity and mortality. In the United States, the most vulnerable age groups are infants and adolescents/young adults, and the most common type of IMD is caused by serogroup B (MenB). MenB is preventable among adolescents and you...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-01-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2023.2212570 |
| _version_ | 1797673047684022272 |
|---|---|
| author | Jessica Presa Cynthia Burman Maria J. Tort Alejandro Cane Joseph A. Bocchini |
| author_facet | Jessica Presa Cynthia Burman Maria J. Tort Alejandro Cane Joseph A. Bocchini |
| author_sort | Jessica Presa |
| collection | DOAJ |
| description | Invasive meningococcal disease (IMD) is rare but associated with high morbidity and mortality. In the United States, the most vulnerable age groups are infants and adolescents/young adults, and the most common type of IMD is caused by serogroup B (MenB). MenB is preventable among adolescents and young adults with the use of two licensed vaccines, MenB-FHbp (Trumenba®, bivalent rLP2086; Pfizer Inc, Collegeville, PA) and MenB-4C (Bexsero®; GSK Vaccines, Srl, Italy). Because the effectiveness of MenB vaccination is dependent on broad vaccine coverage across circulating disease-causing strains, we reviewed the available clinical and real-world evidence regarding breadth of coverage of the two licensed vaccines in adolescents and young adults in the United States. Both vaccines protect against various MenB strains. More controlled data regarding breadth of coverage across MenB strains are available for MenB-FHbp compared with MenB-4C, whereas more observational data regarding US outbreak strain susceptibility are available for MenB-4C. |
| first_indexed | 2024-03-11T21:39:50Z |
| format | Article |
| id | doaj.art-7f73830082f94230b31fa9d585f6087f |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:39:50Z |
| publishDate | 2023-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-7f73830082f94230b31fa9d585f6087f2023-09-26T13:25:50ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2023-01-0119110.1080/21645515.2023.22125702212570Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adultsJessica Presa0Cynthia Burman1Maria J. Tort2Alejandro Cane3Joseph A. Bocchini4Pfizer IncPfizer IncPfizer IncPfizer IncWillis-Knighton Health SystemInvasive meningococcal disease (IMD) is rare but associated with high morbidity and mortality. In the United States, the most vulnerable age groups are infants and adolescents/young adults, and the most common type of IMD is caused by serogroup B (MenB). MenB is preventable among adolescents and young adults with the use of two licensed vaccines, MenB-FHbp (Trumenba®, bivalent rLP2086; Pfizer Inc, Collegeville, PA) and MenB-4C (Bexsero®; GSK Vaccines, Srl, Italy). Because the effectiveness of MenB vaccination is dependent on broad vaccine coverage across circulating disease-causing strains, we reviewed the available clinical and real-world evidence regarding breadth of coverage of the two licensed vaccines in adolescents and young adults in the United States. Both vaccines protect against various MenB strains. More controlled data regarding breadth of coverage across MenB strains are available for MenB-FHbp compared with MenB-4C, whereas more observational data regarding US outbreak strain susceptibility are available for MenB-4C.http://dx.doi.org/10.1080/21645515.2023.2212570adolescentyoung adultmeningococcal diseasemeningococcal infectionsvaccinationvaccines |
| spellingShingle | Jessica Presa Cynthia Burman Maria J. Tort Alejandro Cane Joseph A. Bocchini Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults Human Vaccines & Immunotherapeutics adolescent young adult meningococcal disease meningococcal infections vaccination vaccines |
| title | Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults |
| title_full | Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults |
| title_fullStr | Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults |
| title_full_unstemmed | Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults |
| title_short | Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults |
| title_sort | serum bactericidal activity against circulating and reference strains of meningococcal serogroup b in the united states a review of the strain coverage of meningococcal serogroup b menb vaccines in adolescents and young adults |
| topic | adolescent young adult meningococcal disease meningococcal infections vaccination vaccines |
| url | http://dx.doi.org/10.1080/21645515.2023.2212570 |
| work_keys_str_mv | AT jessicapresa serumbactericidalactivityagainstcirculatingandreferencestrainsofmeningococcalserogroupbintheunitedstatesareviewofthestraincoverageofmeningococcalserogroupbmenbvaccinesinadolescentsandyoungadults AT cynthiaburman serumbactericidalactivityagainstcirculatingandreferencestrainsofmeningococcalserogroupbintheunitedstatesareviewofthestraincoverageofmeningococcalserogroupbmenbvaccinesinadolescentsandyoungadults AT mariajtort serumbactericidalactivityagainstcirculatingandreferencestrainsofmeningococcalserogroupbintheunitedstatesareviewofthestraincoverageofmeningococcalserogroupbmenbvaccinesinadolescentsandyoungadults AT alejandrocane serumbactericidalactivityagainstcirculatingandreferencestrainsofmeningococcalserogroupbintheunitedstatesareviewofthestraincoverageofmeningococcalserogroupbmenbvaccinesinadolescentsandyoungadults AT josephabocchini serumbactericidalactivityagainstcirculatingandreferencestrainsofmeningococcalserogroupbintheunitedstatesareviewofthestraincoverageofmeningococcalserogroupbmenbvaccinesinadolescentsandyoungadults |